Work Here?
Overview
Entourage combines a venture studio with an early-stage venture capital fund to support startups from two angles. It acts as a creator and builder of new companies (the venture studio) by developing ideas, forming teams, and launching ventures, while also providing seed-stage investment (the early-stage VC) to external founders and portfolio companies. In practice, founders can access hands-on support, resources, and both incubation and funding under one roof, helping turn ideas into companies and help growing startups get early funding. The company differentiates itself by pairing company-building capabilities with early-stage investing in a single organization, offering a coordinated approach rather than a traditional separation between studios and investors. Its goal is to accelerate the creation and growth of high-potential startups by providing both the creation engine and the capital to scale.
About Entourage
Industries
Venture Capital
Financial Services
Company Size
11-50
Company Stage
N/A
Total Funding
$193.3M
Headquarters
Ghent, Belgium
Founded
2024
Get referred to Entourage
See people who can refer or advise you
Simplify's Take
What believers are saying
- Entourage co-led kausable's €12 million round in July 2026, boosting AI credibility.
- Dytto's February 2026 financing shows repeatable early-stage sourcing and conviction.
- Goldi.ai lists twenty investments by September 2026, signaling accelerating deployment pace.
What critics are saying
- Early-stage concentration leaves Entourage exposed if 2026 portfolio companies miss product-market fit.
- The studio model depends on In The Pocket's operating support and founder throughput.
- If exits stay scarce through 2028, successor fundraising collapses and the platform stalls.
What makes Entourage unique
- Entourage combines a €30 million fund with a venture studio in Ghent.
- In The Pocket backs the studio, giving founders access to 200 engineers and designers.
- Its 2026 deals, kausable and Dytto, show disciplined focus on European B2B software.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$193.3M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Flexible Work Hours
Company News
The startup is developing causal "world models" trained on synthetic data that can adapt to new situations from only a handful of examples, targeting applications from robotics to healthcare.
kausable raises €12M to build AI models that learn and adapt without retraining. German startup kausable, which develops reasoning-first AI models designed to adapt to changing environments without continuous retraining, has secured €12 million in a seed funding round led by UVC Partners and Entourage, with participation from HTGF, Mätch VC, and several AI industry and academic angel investors. * Established in 2025 by Johannes Haux, Dr Benjamin Herdeanu, and Gregor Ramien, kausable is a Heidelberg-based AI startup developing frontier AI models that can learn from limited examples and adapt to new situations without requiring constant retraining. * The company builds causal "world models" that learn cause-and-effect relationships rather than relying solely on patterns identified from large datasets. Its models are trained using synthetic causal data, enabling them to understand how systems behave and apply that knowledge to unfamiliar scenarios with only a small number of examples. * The technology is designed to improve AI efficiency in areas such as robotics, healthcare, forecasting, and industrial systems, where adapting to changing environments remains a major challenge. Details of the deal. * With the fresh capital, the company plans to expand its nine-person team, advance its rapid-learning frontier AI model, and move from research toward commercial applications by testing its technology with early customers across sectors including robotics, healthcare, forecasting, and industrial systems.
Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform. The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with pharmaceutical companies. Sightera Biosciences, a Belgian techbio company using generative AI to develop novel small-molecule therapies, has raised €3 million in a pre-seed funding round led by Entourage, Anacura and QBIC. A spin-off from the University of Antwerp and Antwerp University Hospital (UZA), Sightera is developing an AI-native drug discovery platform focused on oncology and fibrosis. Unlike many AI drug discovery companies that rely on public or generic datasets, Sightera trains its models using proprietary data generated from patient-derived biological samples collected from individuals with advanced, therapy-resistant disease. These samples are used to create preclinical models, including organoids, that closely replicate human disease biology and generate large-scale drug-response datasets. The proprietary datasets underpin Sightera's AI platform, enabling it to design small molecules based on biological responses observed in patient-derived systems rather than chemical properties alone. By placing human disease biology at the centre of the discovery process, the company aims to improve the likelihood that AI-designed drug candidates will translate successfully into clinical development. The funding will support the expansion of Sightera's AI-powered drug discovery platform, accelerate the development of its preclinical pipeline and advance its lead molecular glue oncology programme towards preclinical candidate selection. The company also plans to strengthen strategic partnerships with pharmaceutical and biotechnology companies while expanding its research, AI and data science teams. Follow the developments in the technology world. What would you like us to deliver to you?
Belgian biotech Sightera Biosciences has raised €3 million in a pre-seed round led by Entourage, Anacura, and QBIC. The University of Antwerp spin-off takes an unconventional approach to AI drug discovery by starting with treatment-resistant patient samples rather than designing molecules first. Sightera grows tissue from patients whose cancer or fibrosis no longer responds to standard treatments into organoids, then runs drug screens. Its AI uses this data to design small molecules tailored to produce the desired biological response. The funding will advance the company's lead molecular glue oncology programme, SIGHT001, toward preclinical candidate selection. The Antwerp-based company, founded in 2024, plans a larger funding round to take SIGHT001 into clinical trials. The global AI drug discovery market was valued at approximately $2.35 billion in 2025.
Warren, a Ghent, Belgium-based developer of a digital workplace pension and financial coaching platform, raised €10m in seed funding
There are no jobs for Entourage right now.
Find jobs on Simplify and start your career today
About Entourage
Industries
Venture Capital
Financial Services
Company Size
11-50
Company Stage
N/A
Total Funding
$193.3M
Headquarters
Ghent, Belgium
Founded
2024
There are no jobs for Entourage right now.
Find jobs on Simplify and start your career today